- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bayer Monsanto hit with USD 165 million verdict over PCBs in Seattle school
A U.S. jury has ordered Bayer's Monsanto to pay $165 million to employees of a school northeast of Seattle who claimed chemicals made by the company called polychlorinated biphenyls, or PCBs, leaked from light fixtures and got them sick.
The Washington state court jury found the company liable for selling products containing PCBs used in the Sky Valley Education Center in Monroe, Washington, that were not safe, and did not include adequate warnings. The award included nearly $50 million in compensatory damages, and $115 million in punitive damages.
The verdict in favor of six teachers and a custodian who said exposure to the PCBs gave them cancer, brain injuries and other issues marks the latest trial loss for the company, which is now facing nearly $870 million in verdicts from alleged PCBs exposure at the Sky Valley center, said an attorney for the plaintiffs.
The company is appealing those verdicts.
Monsanto said in a statement that it will contest Monday's verdict, and that blood, air and other tests show the school employees were not exposed to unsafe levels of PCBs.
PCBs are chemicals once widely used to insulate electrical equipment and in other common products like carbon copy paper, caulking, floor finish and paint. The U.S. government outlawed the chemicals in 1979 after discovering links to cancer.
Employees, students and others have claimed in numerous lawsuits against the company that exposure to PCBs at the Sky Valley center caused their cancers, thyroid conditions and other health problems.
The company said on Monday it stopped producing PCBs in 1977. It also said the school had been warned repeatedly since the 1990s that its light fixtures needed to be retrofitted, but those warnings were ignored.
The lawsuit named Monsanto spinoff Pharmacia as the defendant in the case, though Monsanto is expected to be required to cover the damages due to legal agreements between the companies governing liabilities from historic chemicals production, according to attorneys for the plaintiffs and financial reports.
Read also: Bayer ordered to pay USD 1.56 billion in latest US trial loss over Roundup weedkiller
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751